EMYRIA LIMITED — Capital/Financing Update 2021

Feb 8, 2021

09/02/2021

ASX Announcement

Emyria adds second Melbourne clinic and engages experienced regulatory consultancy ahead of EMD-003 registration trials

Highlights:

• Emyria has added a second Emerald Clinics site in Melbourne on the back of record appointment growth nationally in January 2021

• New premises in East Melbourne are co-located with Victorian Counseling and Psychological Services (VCPS) , boosting Emyria’s access to mental health services ahead of registration trials for drug program EMD-003 - targeting unmet needs in mental health

• Emyria has also engaged a well established regulatory consultancy with prior Schedule 3 successes to support the registration of EMD-003

• Further expansion opportunities at the same site are in planning to support potential delivery of evidence-generating psychedelic-assisted therapy trials with partner, Mind Medicine Australia

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development company, is pleased to announce the expansion of its clinical service subsidiary - Emerald Clinics - with the addition of a second site in Melbourne. The expansion comes off the back of record patient appointments in January 2021.

EMD-003 registration support and new clinical model development

The new East Melbourne site is co-located with Victorian Counseling and Psychological Services (VCPS) - a major provider of mental health services across Melbourne. VCPS houses clinical psychologists, counsellors and psychiatrists.

==> picture [175 x 163] intentionally omitted <==

The East Melbourne location is expected to increase patient access to Emerald Clinics as well as support pivotal registration trials planned for Emyria’s first drug development program, EMD-003, which is targeting unmet needs in mental health as seeking registration as a Schedule 3 medicine. (See ASX release 05 Jan 21)

To further support the registration of EMD-003, Emyria has also partnered with a well established regulatory affairs consultancy with prior experience and success in Schedule 3 registrations.

VCPS East Melbourne

The VCPS location is also being evaluated as a potential site for psychedelic-assisted therapy trials which are currently being developed in partnership with Mind Medicine Australia (See ASX release 19 Nov 20).

1

==> picture [137 x 40] intentionally omitted <==

Recent recognition of Emyria’s remote monitoring platform With the addition of the second site in Melbourne, Emerald Clinics will be operating its evidence-generating care model from six locations around Australia. Each Emerald Clinics site gathers high quality clinical data with consenting patients using a bespoke data platform. To date, Emyria has used this platform to gather detailed product, safety and efficacy data with over 3,000 patients prescribed pharmaceutical-grade cannabinoids. The Emyria data asset is one of the largest clinical-trial grade data sets in the world and helps improve care for Emerald Clinic’s patients as well as provide a source of unique IP and drug development insights.

Emyria’s digital health and remote monitoring platform was recently recognised with a successful grant award from Western Australia’s Future Health Research and Innovation Fund (FHRI). The grant award of $880,000 was won with research partner, the University of Western Australia. Emyria’s technology and clinical team will play a lead role in the grant which aims to improve the way clinical and mental health of vulnerable patients is monitored remotely. (see ASX release 05 Feb 21)

Emyria’s Managing Director, Dr Michael Winlo, said: “We are pleased to be able to respond to the high patient demand for our clinical care model across Australia with the addition of a new site in Melbourne. The new site is unique in that it is co-located with Victorian Counseling and Psychological Services and offers unique collaboration opportunities with mental health clinicians including psychologists and psychiatrists.

We anticipate that these collaborations will assist our pivotal drug registration clinical trials for EMD-003 - a cannabinoid medicine targeting unmet needs in mental health - as well as support the development of evidence-based clinical protocols and therapy standards for psychedelic-assisted therapy trials. Such trials are currently in development with partner Mind Medicine Australia to help improve our understanding of the role these treatments might play in treating serious mental health concerns like PTSD and major depression.”

The second Melbourne Emerald Clinics location is at - 62 Wellington Parade, East Melbourne - and opens on February 15, 2021.

For further information:

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

2

==> picture [137 x 40] intentionally omitted <==

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

3